发明名称 |
VLA-4 INHIBITORY DRUG |
摘要 |
<p>There is provided a VLA-4 inhibitory drug having good oral absorbability and exhibiting sufficient anti-inflammatory effects when administered orally. A compound represented by the following formula (I):
wherein R 1 represents a hydrogen atom or a C1-8 alkyl group; R 2 represents a hydrogen atom, a halogen atom, a C1-8 alkoxy group, orabenzyloxygroupwhichmaybe substituted; Q represents a monocyclic or bicyclic nitrogen-containing heterocyclic group which may be substituted, and has a nitrogen atom as the bonding site; Y represents an oxygen atom or CH 2 ; W represents a bicyclic aromatic hydrocarbon ring group which may be substituted, or a bicyclic aromatic heterocyclic group whichmaybe substituted; R 3a , R 3b and R 3c each independently represent a hydrogen atom, a halogen atom, a C1-8 alkoxy group or a C1-8 alkyl group; and A 1 represents a nitrogen atom or C-R 3d (wherein R 3d represents a hydrogen atom, a halogen atom, a C1-8 alkoxy group or a C1-8 alkyl group),
or a salt thereof, or a VLA-4 inhibitory drug comprising the compound or the salt as an active ingredient.</p> |
申请公布号 |
EP1961750(B1) |
申请公布日期 |
2013.09.18 |
申请号 |
EP20060834580 |
申请日期 |
2006.12.13 |
申请人 |
DAIICHI SANKYO COMPANY, LIMITED |
发明人 |
MACHINAGA, NOBUO;IIMURA, SHIN;YONEDA, YOSHIYUKI;CHIBA, JUN;MURO, FUMIHITO;HOH, HIDEKO;NAKAYAMA, ATSUSHI |
分类号 |
C07D401/12;A61K31/4025;A61K31/404;A61K31/407;A61K31/416;A61K31/4178;A61K31/422;A61K31/427;A61K31/454;A61K31/4725;A61K31/496;A61P29/00;C07D401/14;C07D403/12;C07D403/14;C07D405/12;C07D405/14;C07D409/14 |
主分类号 |
C07D401/12 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|